Rexlemestrocel-L

Summary

Rexlemestrocel-L (CHEMBL3545318) is a phase-3 clinical-stage cell; indicated across 2 conditions including intervertebral disk degenerative disorder and hypoplastic left heart syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Cell
• Indications: 2 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3545318
Name	Rexlemestrocel-L
Type	Cell
Max phase	3

Also known as: Neofuse, Rexlemestrocel-l, Revascor, REXLEMESTROCEL-L

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
intervertebral disk degenerative disorder	3	MONDO:0011385	HP:0008419
hypoplastic left heart syndrome	1	MONDO:0004933	MONDO:0004933

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	3
PHASE1/PHASE2	3
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06325566	PHASE3	RECRUITING	Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain
NCT02032004	PHASE3	COMPLETED	Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure
NCT02412735	PHASE3	COMPLETED	Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain
NCT00549913	PHASE1/PHASE2	COMPLETED	Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF)
NCT01097486	PHASE2	COMPLETED	Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy
NCT01106417	PHASE1/PHASE2	COMPLETED	Safety and Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion
NCT03079401	PHASE1/PHASE2	UNKNOWN	Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).